
The chief medical officer of Triumvira Immunologics discussed promising early results from the company’s phase 1/2 clinical trial.
The chief medical officer of Triumvira Immunologics discussed promising early results from the company’s phase 1/2 clinical trial.
The chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed how academia and industry can work best with regulatory agencies.
The chief medical officer of Triumvira Immunologics discussed the company’s TAC platform and its versatile target-recognizing domain.
Raphaël G. Ognar, chief executive officer and co-founder of NKILT Therapeutics, discussed approaches to help increase patient access to cell therapies.
Geoffrey Hodge, chief executive officer of SOTIO Biotech US, discussed the company's development of the BOXR cell therapy platform.
The associate director of Research at Senti Biosciences discussed the company's research on using logic-gated CAR-NK cells for the treatment of AML and solid tumors.
The chief scientific officer at TScan Therapeutics discussed the company’s SafetyScan technology.
The co-founder and executive chairman of TC BioPharm discussed his thoughts on the regulatory, logistical, and quality hurdles of manufacturing cell therapies.
The senior director and clinical program leader, Translational Clinical Oncology at Novartis Institutes for BioMedical Research, discussed new data from the phase 1 study.
The professor of medicine and University of Minnesota Medical School discussed the advantages and unmet needs of natural killer cells in oncology.
The research fellow from Harvard Medical School discussed blocking IFNg as a potential approach to reduce toxicities.
The instructor of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania discussed his thoughts on the potential of targeting mutant KRAS with immunotherapy.
The chief of cancer immunotherapy at Rutgers Cancer Institute discussed clinical results with different cell therapy approaches.
The scientist at A2 Biotherapeutics discussed the company’s dual-receptor Tmod technology.
The acting chief of the oncology branch of the Center for Biologics Evaluation and Research at the FDA discussed the evolution of cell therapies in the past decade.